US Healthcare AI Regulation: Why Governance and Strategy Need to Move Together
- May 3
- 3 min read
Artificial intelligence is moving quickly across healthcare. Health systems, life sciences companies, startups, and digital health teams are evaluating AI across clinical workflows, diagnostics, documentation, patient engagement, operations, and research.
The regulatory conversation is moving with it.
For healthcare leaders, the central issue is not only whether an AI tool works. It is whether the organization has the governance structure to evaluate, implement, monitor, and update that tool responsibly.
Healthcare AI Regulation Is Not One Lane
In the United States, healthcare AI sits across multiple regulatory and oversight domains.
The FDA plays a key role when AI functions as software as a medical device or influences diagnosis, treatment, or other clinical decisions. The FDA also maintains a public list of AI-enabled medical devices authorized for marketing in the United States, which continues to grow as clinical AI adoption expands.
HIPAA remains central when AI tools use protected health information. Privacy, access controls, data security, vendor management, and documentation all become part of the AI governance conversation.
The FTC also has a role when AI products are marketed to consumers, clinicians, or healthcare organizations. Claims about what AI tools can do need to be accurate, supported, and not misleading. The FTC’s consumer protection role is especially relevant as more AI tools enter patient-facing and enterprise settings.
Intended Use Should Drive the Governance Approach
Not every AI tool carries the same risk.
An AI tool used for back-office scheduling raises different questions than one used for radiology, triage, clinical decision support, or patient-facing medical guidance.
That is why intended use matters.
Before an organization adopts an AI tool, leaders should be clear on:
What the tool is intended to do
Who will use it
Whether it influences clinical decision-making
What data does it rely on
What evidence supports its use
How will performance be monitored after deployment
Who is accountable when the tool affects workflow or care
This is where regulatory strategy and AI governance begin to overlap.
AI Governance Is the Operating Structure Around Regulation
Regulation sets expectations. Governance helps organizations operationalize them.
A healthcare AI governance structure should bring together the right stakeholders early: clinical leaders, IT, data science, privacy, cybersecurity, legal, compliance, procurement, operations, quality, safety, and executive leadership.
The goal is not to slow adoption. The goal is to create a clearer process for deciding which AI tools to adopt, how to evaluate them, and how to monitor them once in use.
For clinical AI, this includes validation in the intended setting, workflow review, user training, escalation pathways, and post-deployment monitoring.
For enterprise AI, this also includes vendor oversight, data governance, documentation, and alignment with organizational strategy.
AI Tools Will Change Over Time
One challenge with AI-enabled tools is that they may evolve after deployment.
The FDA’s work on predetermined change control plans reflects this reality. These plans are designed to support certain planned modifications to AI-enabled medical device software while maintaining reasonable assurance of safety and effectiveness.
For healthcare organizations, the takeaway is practical: implementation is not the endpoint.
AI governance needs to account for updates, performance drift, workflow changes, user behavior, and real-world impact over time.
The Executive Takeaway
Healthcare AI regulation should not be treated as a separate legal exercise.
It should be part of the organization’s broader AI strategy.
That means leaders need to understand the regulatory environment, but also build the internal structures needed to govern AI responsibly.
The organizations best positioned for AI adoption will be the ones that can connect:
regulatory readiness
data governance
clinical validation
workflow integration
vendor oversight
monitoring
accountability
enterprise strategy
Responsible AI in healthcare is not only about model performance.
It is about whether the organization is prepared to use AI safely, credibly, and at scale.
At CROSS Global Research & Strategy, we focus on the intersection of AI governance, responsible AI strategy, and healthcare implementation.
For organizations evaluating AI adoption, the first step is often not another tool. It is a clearer view of the governance structure needed to use AI responsibly over time.
Comments